Xavier’s career has spanned time in biotech and pharma. At Kudos Pharmaceuticals/AstraZeneca, the company responsible for the discovery of the first PARP inhibitor (Lynparza®), he led the preclinical ATR project. He has also worked at Hybrigenics and co-founded MISSION Therapeutics where he further developed his deep understanding of the ubiquitin proteasome pathway. Additionally, Xavier has worked for Sanofi-Synthelabo and Lectus Therapeutics.

Prior to a post-doctoral position at Colombia University (NYC, USA), in oncology, Xavier received his Ph.D in Biochemistry from Louis Pasteur University in Strasbourg, France.